- Home
- RGP vs AGEN Comparison
RGP vs AGEN Comparison
Compare RGP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- AGEN
- Stock Information
- Founded
- RGP 1996
- AGEN 1994
- Country
- RGP United States
- AGEN United States
- Employees
- RGP N/A
- AGEN N/A
- Industry
- RGP Business Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGP Consumer Discretionary
- AGEN Health Care
- Exchange
- RGP Nasdaq
- AGEN Nasdaq
- Market Cap
- RGP 155.0M
- AGEN 142.8M
- IPO Year
- RGP 2006
- AGEN 2000
- Fundamental
- Price
- RGP $4.84
- AGEN $4.28
- Analyst Decision
- RGP Buy
- AGEN Buy
- Analyst Count
- RGP 2
- AGEN 2
- Target Price
- RGP $6.00
- AGEN $14.50
- AVG Volume (30 Days)
- RGP 299.8K
- AGEN 456.4K
- Earning Date
- RGP 10-08-2025
- AGEN 11-11-2025
- Dividend Yield
- RGP 5.77%
- AGEN N/A
- EPS Growth
- RGP N/A
- AGEN N/A
- EPS
- RGP N/A
- AGEN N/A
- Revenue
- RGP $551,331,000.00
- AGEN $101,706,000.00
- Revenue This Year
- RGP N/A
- AGEN $60.49
- Revenue Next Year
- RGP $12.36
- AGEN N/A
- P/E Ratio
- RGP N/A
- AGEN N/A
- Revenue Growth
- RGP N/A
- AGEN N/A
- 52 Week Low
- RGP $4.44
- AGEN $1.38
- 52 Week High
- RGP $9.96
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- RGP 40.50
- AGEN 44.68
- Support Level
- RGP $4.86
- AGEN $3.78
- Resistance Level
- RGP $5.08
- AGEN $4.80
- Average True Range (ATR)
- RGP 0.21
- AGEN 0.26
- MACD
- RGP -0.04
- AGEN -0.01
- Stochastic Oscillator
- RGP 10.63
- AGEN 40.34
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).